Literature DB >> 15479669

T cell apoptosis and inflammatory bowel disease.

M P Peppelenbosch1, S J H van Deventer.   

Abstract

Entities:  

Mesh:

Year:  2004        PMID: 15479669      PMCID: PMC1774279          DOI: 10.1136/gut.2004.040824

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  17 in total

1.  Resistance of Crohn's disease T cells to multiple apoptotic signals is associated with a Bcl-2/Bax mucosal imbalance.

Authors:  K Ina; J Itoh; K Fukushima; K Kusugami; T Yamaguchi; K Kyokane; A Imada; D G Binion; A Musso; G A West; G M Dobrea; T S McCormick; E G Lapetina; A D Levine; C A Ottaway; C Fiocchi
Journal:  J Immunol       Date:  1999-07-15       Impact factor: 5.422

2.  Divergent cell cycle kinetics underlie the distinct functional capacity of mucosal T cells in Crohn's disease and ulcerative colitis.

Authors:  A Sturm; A Z A Leite; S Danese; K A Krivacic; G A West; S Mohr; J W Jacobberger; C Fiocchi
Journal:  Gut       Date:  2004-11       Impact factor: 23.059

3.  A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

Authors:  S R Targan; S B Hanauer; S J van Deventer; L Mayer; D H Present; T Braakman; K L DeWoody; T F Schaible; P J Rutgeerts
Journal:  N Engl J Med       Date:  1997-10-09       Impact factor: 91.245

4.  Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo.

Authors:  R Atreya; J Mudter; S Finotto; J Müllberg; T Jostock; S Wirtz; M Schütz; B Bartsch; M Holtmann; C Becker; D Strand; J Czaja; J F Schlaak; H A Lehr; F Autschbach; G Schürmann; N Nishimoto; K Yoshizaki; H Ito; T Kishimoto; P R Galle; S Rose-John; M F Neurath
Journal:  Nat Med       Date:  2000-05       Impact factor: 53.440

5.  Decreased Bax expression by mucosal T cells favours resistance to apoptosis in Crohn's disease.

Authors:  J Itoh; C de La Motte; S A Strong; A D Levine; C Fiocchi
Journal:  Gut       Date:  2001-07       Impact factor: 23.059

6.  Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease.

Authors:  T ten Hove; C van Montfrans; M P Peppelenbosch; S J H van Deventer
Journal:  Gut       Date:  2002-02       Impact factor: 23.059

7.  Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial.

Authors:  W J Sandborn; S B Hanauer; S Katz; M Safdi; D G Wolf; R D Baerg; W J Tremaine; T Johnson; N N Diehl; A R Zinsmeister
Journal:  Gastroenterology       Date:  2001-11       Impact factor: 22.682

8.  Lamina propria T cells in Crohn's disease and other gastrointestinal inflammation show defective CD2 pathway-induced apoptosis.

Authors:  M Boirivant; M Marini; G Di Felice; A M Pronio; C Montesani; R Tersigni; W Strober
Journal:  Gastroenterology       Date:  1999-03       Impact factor: 22.682

9.  Induction of T lymphocyte apoptosis by sulphasalazine in patients with Crohn's disease.

Authors:  J Doering; B Begue; M J Lentze; F Rieux-Laucat; O Goulet; J Schmitz; N Cerf-Bensussan; F M Ruemmele
Journal:  Gut       Date:  2004-11       Impact factor: 23.059

10.  Enhanced DNA damage-induced p53 peptide phosphorylation and cell-cycle arrest in Sjögren's syndrome cells.

Authors:  G Henriksson; M Brant; A Sallmyr; S Fukushima; R Manthorpe; A Bredberg
Journal:  Eur J Clin Invest       Date:  2002-06       Impact factor: 4.686

View more
  17 in total

1.  Dopamine D2 receptor polymorphisms in inflammatory bowel disease and the refractory response to treatment.

Authors:  F Magro; E Cunha; F Araujo; E Meireles; P Pereira; M Dinis-Ribeiro; F Tavarela Veloso; R Medeiros; P Soares-da-Silva
Journal:  Dig Dis Sci       Date:  2006-09-15       Impact factor: 3.199

Review 2.  Immunopathogenesis of IBD: insufficient suppressor function in the gut?

Authors:  I L Huibregtse; A U van Lent; S J H van Deventer
Journal:  Gut       Date:  2006-10-17       Impact factor: 23.059

3.  PUMA-mediated intestinal epithelial apoptosis contributes to ulcerative colitis in humans and mice.

Authors:  Wei Qiu; Bin Wu; Xinwei Wang; Monica E Buchanan; Miguel D Regueiro; Douglas J Hartman; Robert E Schoen; Jian Yu; Lin Zhang
Journal:  J Clin Invest       Date:  2011-04-01       Impact factor: 14.808

4.  Moxibustion inhibits interleukin-12 and tumor necrosis factor alpha and modulates intestinal flora in rat with ulcerative colitis.

Authors:  Xiao-Mei Wang; Yuan Lu; Lu-Yi Wu; Shu-Guang Yu; Bai-Xiao Zhao; Hong-Yi Hu; Huan-Gan Wu; Chun-Hui Bao; Hui-Rong Liu; Jin-Hai Wang; Yi Yao; Xue-Gui Hua; Hui-Ying Guo; Li-Rong Shen
Journal:  World J Gastroenterol       Date:  2012-12-14       Impact factor: 5.742

5.  Role of DOR-β-arrestin1-Bcl2 signal transduction pathway and intervention effects of oxymatrine in ulcerative colitis.

Authors:  Pi-Qi Zhou; Heng Fan; Hui Hu; Qing Tang; Xing-Xing Liu; Li-Juan Zhang; Min Zhong; Zhe-Xing Shou
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2014-12-06

Review 6.  Hematopoietic cell transplantation for Crohn's disease; is it time?

Authors:  Y Leung; M Geddes; J Storek; R Panaccione; P L Beck
Journal:  World J Gastroenterol       Date:  2006-11-07       Impact factor: 5.742

7.  Association between CTLA-4 gene promoter (49 A/G) in exon 1 polymorphisms and inflammatory bowel disease in the Tunisian population.

Authors:  Walid Ben Alaya; Imen Sfar; Houda Aouadi; Saloua Jendoubi; Tawfik Najjar; Azza Filali; Yousr Gorgi; Taieb Ben Abdallah; Leila Mouelhi; Samira Matri; Khaled Ayed
Journal:  Saudi J Gastroenterol       Date:  2009-01       Impact factor: 2.485

Review 8.  Prevention of colitis-associated cancer: natural compounds that target the IL-6 soluble receptor.

Authors:  Cate Moriasi; Dharmalingam Subramaniam; Shanjana Awasthi; Satish Ramalingam; Shrikant Anant
Journal:  Anticancer Agents Med Chem       Date:  2012-12       Impact factor: 2.505

9.  E. coli-produced BMP-2 as a chemopreventive strategy for colon cancer: a proof-of-concept study.

Authors:  Saravanan Yuvaraj; Sa'ad H Al-Lahham; Rajesh Somasundaram; Patrick A Figaroa; Maikel P Peppelenbosch; Nicolaas A Bos
Journal:  Gastroenterol Res Pract       Date:  2012-01-19       Impact factor: 2.260

10.  Infliximab in ulcerative colitis.

Authors:  Avi Levin; Oren Shibolet
Journal:  Biologics       Date:  2008-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.